MTOR and cancer: In this context, a synergistic effect could be obtained by combining mTOR kinase inhibitors with anti-cancer drug-activating caspases, giving rise to a strong repression of the mTORC1 and thus offering new therapeutic perspectives for a large range of human diseases.